About PrecisionRNA Biotech Pvt Ltd.
PrecisionRNA Biotech Pvt. Ltd. (PreRNA) is a healthcare innovation company leading the way in next-generation diagnostics. Our mission is to decode disease biology at a molecular level, enabling earlier, more accurate, and more affordable detection methods.
About CANTEL
CANTEL is India’s first microRNA-based blood test for breast cancer screening. Detects breast cancer at Stage 0 (DCIS), much earlier than imaging or symptom-based methods. Uses proprietary miRNA signatures validated through peer-reviewed research. Minimally invasive, accurate, and cost-effective.
In 2022, breast cancer caused 2.3 million diagnoses and 670,000 deaths globally.
Source: GLOBOCAN 2022
Every 14 seconds, a woman is diagnosed with breast cancer worldwide.
Source: Breast Cancer Foundation
Breast cancer is the most common cancer in women in 157 of 185 countries.
Source: WHO
Vision
To democratize early detection of breast cancer and other diseases by making cutting-edge diagnostics accessible to every woman in India.
Mission
To combine deep science, advanced bioinformatics, and scalable models to deliver early, accurate, and affordable screening solutions that save lives.
Values
Innovation
Accessibility
Impact
Why CANTEL is a Game-Changer
Detects breast cancer at Stage 0 (DCIS) before symptoms appear
Minimally invasive, affordable, accessible and accurate
It does not merely predict the risk but it detects the presence of breast cancer
Eliminates diagnostic delays with end-to-end infrastructure.
Globally patented technology and advanced bioinformatics.
